Severe necrosis due to paclitaxel extravasation

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 163-165

  Herrington, Jon D ^a,b   Figueroa, José A ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; ARTICLE; BREAST CARCINOMA; CASE REPORT; CLINICAL FEATURE; DEBRIDEMENT; DRUG EXTRAVASATION; DRUG INFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; SPINE METASTASIS; TISSUE NECROSIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ERUPTIONS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; FOREARM; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NECROSIS; PACLITAXEL; SPINAL NEOPLASMS;

EID: 0031036382     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
2. Kohler DR, Goldspiel BR. Paclitaxel (Taxol). Pharmacotherapy 1994;14:3-34.
3. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20(suppl 3):1-15.
4. Noone MH, McCabe MS, Denicoff AM, Lepore JM. Nursing management of the patient receiving Taxol therapy. Monogr Natl Cancer Inst 1993;15:149-54.
5. Lubejko BG, Sartorius SE. Nursing considerations in paclitaxel (Taxol) administration. Semin Oncol 1993;20(suppl 3):26-30.
6. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 1994;86:51-3.
7. Raymond E, Cartier S, Canuel C, et al. Extravasation de paclitaxel (Taxol). Rev Med Interne 1995;16:141-2.
8. National Cancer Institute, Southwest Oncology Group. Southwest oncology group toxicity criteria. In: Haskell CM, ed. Cancer treatment, 4th ed. Philadelphia: WB Saunders, 1995:1164-9.
9. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:1171-7.
10. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal Taxol: a gynecologic [sic] oncology group study. J Clin Oncol 1992;10:1485-91.
11. Shapiro J, Richardson GE. Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 1994;12:2237-8.
12. Meehan JL, Sporn JR. Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation. J Natl Cancer Inst 1994;86:1250-1.
13. DuBois A, Kommoss FGM, Pfisterer J, Lück HJ, Meerpohl HG. Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. Gynecol Oncol 1996;60:94-6.
14. Rogers BB. An author responds: extravasation of paclitaxel at peripheral sites [letter]. Oncol Nurs Forum 1994;21:973.
15. Goodman M, Stewart I, Lydon J, Blendowski C, Barnicle M. Use caution when managing paclitaxel and taxotere infiltrations [letter]. Oncol Nurs Forum 1996;23:541-2.
16. Dorr RT, Snead K, Liddil JD. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 1996;78:152-6.
17. DuBois A, Fehr MK, Bochtler H, Koechli OR. Clinical course and management of paclitaxel extravasation. Oncol Rep 1996;3:973-4.